Skip to main content
Addgene

MFE23-ZZ
(Plasmid #223553)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 223553 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pET302NT-his
  • Backbone manufacturer
    Thermofisher
  • Backbone size w/o insert (bp) 5712
  • Total vector size (bp) 6953
  • Vector type
    Bacterial Expression

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    BL21 (DE3)
  • Copy number
    Unknown

Gene/Insert

  • Gene/Insert name
    pET302-MFE23-ZZ
  • Species
    M. musculus (mouse); S. aureus
  • Insert Size (bp)
    1269
  • Promoter T7
  • Tags / Fusion Proteins
    • HA tag (N terminal on insert)
    • HIS tag (N terminal on backbone)

Cloning Information

  • Cloning method Unknown
  • 5′ sequencing primer 5′-TAATACGACTCACTATAGGG-3′
  • 3′ sequencing primer 5’-TAGTTATTGCTCAGCGGTGG-3’
  • (Common Sequencing Primers)

Resource Information

  • A portion of this plasmid was derived from a plasmid made by
    Thermofisher Geneart Gene Synthesis

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

Addgene comment: Note that there are some differences between the Addgene verified sequence and the depositor's reference sequence (see supplemental document). These differences do not affect the function of the plasmid.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    MFE23-ZZ was a gift from Jean Gariepy (Addgene plasmid # 223553 ; http://n2t.net/addgene:223553 ; RRID:Addgene_223553)
  • For your References section:

    Broadly Applicable Bispecific Linker Approach to Noncovalently Target Therapeutic Nanoparticles to Tumor Cells Expressing Carcinoembryonic Antigen. Fernando A, Sparkes A, Matus EI, Patel A, Foster FS, Goertz D, Lee P, Gariepy J. ACS Pharmacol Transl Sci. 2024 Jun 3;7(6):1864-1873. doi: 10.1021/acsptsci.4c00140. eCollection 2024 Jun 14. 10.1021/acsptsci.4c00140 PubMed 38898951